244 related articles for article (PubMed ID: 26121434)
1. SIGNIFICANT ELEVATION OF GROWTH HORMONE LEVEL IMPACTS SURGICAL OUTCOMES IN ACROMEGALY.
Anthony JR; Alwahab UA; Kanakiya NK; Pontell DM; Veledar E; Oyesiku NM; Ioachimescu AG
Endocr Pract; 2015 Sep; 21(9):1001-9. PubMed ID: 26121434
[TBL] [Abstract][Full Text] [Related]
2. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
3. [Outcome of surgical treatment for acromegaly performed by a single neurosurgeon and cumulative meta-analysis].
Boeving A; Borba LA; Rodrigues AM; Orichowski EB; Paz Filho GJ; Santos CM; Boguszewski CL
Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):884-92. PubMed ID: 17160212
[TBL] [Abstract][Full Text] [Related]
4. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD
Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787
[TBL] [Abstract][Full Text] [Related]
5. Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly.
Park SH; Ku CR; Moon JH; Kim EH; Kim SH; Lee EJ
J Clin Endocrinol Metab; 2018 Mar; 103(3):909-916. PubMed ID: 29272449
[TBL] [Abstract][Full Text] [Related]
6. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.
Freda PU; Wardlaw SL; Post KD
J Neurosurg; 1998 Sep; 89(3):353-8. PubMed ID: 9724106
[TBL] [Abstract][Full Text] [Related]
7. Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays.
Sarkar S; Jacob KS; Pratheesh R; Chacko AG
Acta Neurochir (Wien); 2014 Jul; 156(7):1379-87; discussion 1387. PubMed ID: 24781680
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.
Taweesomboonyat C; Oearsakul T
World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643
[TBL] [Abstract][Full Text] [Related]
9. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
10. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
Hofstetter CP; Mannaa RH; Mubita L; Anand VK; Kennedy JW; Dehdashti AR; Schwartz TH
Neurosurg Focus; 2010 Oct; 29(4):E6. PubMed ID: 20887131
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission.
Starke RM; Raper DM; Payne SC; Vance ML; Oldfield EH; Jane JA
J Clin Endocrinol Metab; 2013 Aug; 98(8):3190-8. PubMed ID: 23737543
[TBL] [Abstract][Full Text] [Related]
13. Predictors of surgical outcome and early criteria of remission in acromegaly.
Antunes X; Ventura N; Camilo GB; Wildemberg LE; Guasti A; Pereira PJM; Camacho AHS; Chimelli L; Niemeyer P; Gadelha MR; Kasuki L
Endocrine; 2018 Jun; 60(3):415-422. PubMed ID: 29626274
[TBL] [Abstract][Full Text] [Related]
14. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Effects of Intracapsular Debulking and Adjuvant Somatostatin Analogs for Growth Hormone-Secreting Pituitary Macroadenoma: 10 Years of Experience in a Single Institute.
Shen SC; Shen CC; Pu TW; Cheng WY
World Neurosurg; 2019 Jun; 126():e41-e47. PubMed ID: 30716503
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL
J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
[TBL] [Abstract][Full Text] [Related]
17. 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly.
Shen M; Chen Z; Shou X; He W; Qiao N; Ma Z; Ye Z; Zhang Y; Zhang Q; Zhou X; Cao X; Zhang Z; Ye H; Li Y; Zhao Y; Li S; He M; Wang Y
J Neuroendocrinol; 2021 May; 33(5):e12958. PubMed ID: 33998086
[TBL] [Abstract][Full Text] [Related]
18. Revisiting the Role of Insulin-like Growth Factor-1 Measurement After Surgical Treatment of Acromegaly.
Jung IH; Choi S; Ku CR; Lee SG; Lee EJ; Kim SH; Kim EH
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2589-e2599. PubMed ID: 33738470
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic Transsphenoidal Approach for Acromegaly with Remission Rates in 401 Patients: 2010 Consensus Criteria.
Anik I; Cabuk B; Gokbel A; Selek A; Cetinarslan B; Anik Y; Ceylan S
World Neurosurg; 2017 Dec; 108():278-290. PubMed ID: 28887283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
